SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction and highlight its price stability within the Solana ecosystem. Discussions also focus on WAGMI's potential for significant revaluation, drawing comparisons to other successful meme coins like DOGE and SHIB. The community emphasizes WAGMI's organic growth and potential for long-term gains, with some anticipating a major breakout.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential for growth and new projects being built on the platform, including meme coins like $SOLYCAT and $CAW. Community members are also closely watching for potential breakout opportunities, emphasizing the importance of conviction and holding through market volatility. Recent news of Fidelity adding Solana support and institutional validation may be contributing to the positive sentiment.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The meme coin "crow with knife" ($CAW) is gaining attention, with community members highlighting its deflationary mechanism and presence across multiple chains like Solana, BSC, CRO, and ETH.  Enthusiasts are also excited about potential staking opportunities and partnerships. Community buzz is focused on its organic growth and strong "cult" following.

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is trending as a new Solana-based meme token, generating buzz around its recent launch and availability on Phantom Wallet. The community is drawn to its potential for high gains, with many emphasizing its momentum within the Solana ecosystem alongside established tokens. Conversations highlight its strong chart and potential breakout.

WISeKey International Holding Ltd. is a cybersecurity company, which engages in offering digital security technology solutions. The firm operates through the Internet of Things (IoT), and Managed Public Key Infrastructure (mPKI) segments. The IoT segment refers to the design, manufacturing, sales and distribution of microprocessors operations. The mPKI segment includes all operations relating to the provision of secured access keys, authentication, signing software, certificates and digital security applications. The company was founded by Joao Carlos Creus Moreira and Philippe Doubre in 1999 and is headquartered in Zug, Switzerland.

WISeKey International Holding Ltd - ADR

WISeKey is trending as investors discuss its potential upside in the post-quantum computing era, particularly in securing satellite constellations. The community is highlighting the company's subsidiaries, including SEALCOIN and WISeSat, and comparing its market cap to its parent company, LAES.  Some investors believe WKEY's current valuation doesn't reflect the value of its assets and potential growth in the quantum security market.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions about stablecoin regulation and adoption, with some highlighting its potential role in cross-border payments. Community members are also closely watching partnerships and integrations with various platforms like Binance and Solana. Additionally, there's chatter around meme coins and stablecoin trading strategies, including discussions about the BROKE coin.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending as the community discusses its potential, partnerships, and possible ETF. A segment of the community is focused on the token's multi-chain presence through projects like $CAW. Others express frustration with price action, debating whether to buy and stake or take profits.

Pump.fun

$PUMP is trending as traders discuss its strong community and potential within the Solana ecosystem, with many mentioning $WAGMI and highlighting the token's resilience. Community members are emphasizing holding for the long term and believe the project is coded for success. The conversation includes discussion of potential catalysts and continued building within the $SOL ecosystem.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as the market anticipates the FDA's decision on their supplemental NDA for Revuforj to treat a specific type of leukemia, expected by October 25th. The community is weighing the potential for label expansion and increased market access against existing concerns around boxed warnings and competitor drugs. Some traders believe that approval is already priced in, while others anticipate a significant surge depending on the scope of the label.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending due to concerns surrounding a recent FDA safety communication regarding allergic reactions to specific lots of its BIVIGAM and ASCENIV products, leading to a stock price drop. While some investors view this as a temporary setback and potential buying opportunity, citing the company's strong financials and growth prospects, others worry about the impact of potential voluntary recalls on revenue and profitability. The community is also discussing the CEO's recent stock sale and speculating about potential short selling or manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition

Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.

How Much Upside is Left in Castle Biosciences (CSTL)? Wall Street Analysts Think 50.08%

The consensus price target hints at a 50.1% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What Makes Castle Biosciences (CSTL) a New Strong Buy Stock

Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates

Castle Biosciences (CSTL) delivered earnings and revenue surprises of +129.41% and +16.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for August 1st

CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline

Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company...

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of gene expression profile...

Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter...

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Castle Biosciences Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

CSTL
Castle Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CSTL News

CSTLCastle Biosciences Inc